ITP Dosing

For your adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment

 

DOPTELET® (avatrombopag): ONE DOSAGE STRENGTH HELPS MAKE TITRATION MANAGEABLE FOR YOU AND YOUR PATIENTS1

Titrate up or down as necessary, based on platelet count (see dosing table below for titration criteria)

Chart: Doptelet dosing

After initiating therapy with DOPTELET, assess platelet counts weekly until a stable platelet count of ≥50x109/L has been achieved, and then obtain platelet counts monthly thereafter. Obtain platelet counts weekly for at least 4 weeks following discontinuation of DOPTELET.

TARGET THE RIGHT RESPONSE FOR YOUR PATIENT1

Initial dosing: Start with 1 tablet (20 mg) once daily with food, then dose-adjust if needed based on platelet count.

DOPTELET® (avatrombopag) dosing table

PLATELET COUNT (×109/L) DOSE ADJUSTMENT OR ACTION
Less than 50 after at least 2 weeks of DOPTELET
  • Increase 1 Dose Level (see figure above)
  • Wait 2 weeks and assess the effects of this regimen and any subsequent dose adjustments
Between 200 and 400
  • Decrease 1 Dose Level (see figure above)
  • Wait 2 weeks and assess the effects of this regimen and any subsequent dose adjustments
Greater than 400
  • Stop DOPTELET
  • Increase platelet monitoring to twice weekly
  • When platelet count is <150×109/L, decrease 1 Dose Level (see figure above) and reinitiate therapy
Less than 50 after
4 weeks of DOPTELET
40 mg once daily
  • Discontinue DOPTELET
Greater than 400 after
2 weeks of DOPTELET
20 mg weekly
  • Discontinue DOPTELET
Doptelet Safety

DOPTELET® (avatrombopag) Safety Profile

The safety profile is based on pooled data from 4 clinical studies.1

Reference:

1. DOPTELET [package insert]. Durham, NC: Dova Pharmaceuticals, Inc.

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

IMPORTANT SAFETY INFORMATION FOR DOPTELET

Warnings and Precautions

DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic immune thrombocytopenia. Thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.

In clinical trials, 7% (9/128) of patients with chronic immune thrombocytopenia treated with DOPTELET developed a thromboembolic event. Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).

DOPTELET should not be administered to patients with chronic immune thrombocytopenia in an attempt to normalize platelet counts. Follow the dosing guidelines to achieve target platelet counts.

Contraindications:  None

Drug Interactions  

Dose adjustments are recommended for patients with chronic immune thrombocytopenia taking moderate or strong dual CYP2C9 and CYP3A4 inducers or inhibitors.

Adverse Reactions

The most common adverse reactions (≥10%) were: headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae and nasopharyngitis.

Please see Full Prescribing Information for DOPTELET® (avatrombopag).

Visit Dova.com for WAC pricing.

 
 

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

IMPORTANT SAFETY INFORMATION FOR DOPTELET

Warnings and Precautions

DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic immune thrombocytopenia. Thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.